A5056453244- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- COVID-19 and healthcare impacts
- Acute Myeloid Leukemia Research
- COVID-19 Clinical Research Studies
- Medical Imaging Techniques and Applications
- Biosimilars and Bioanalytical Methods
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Biomedical and Engineering Education
- Blood disorders and treatments
- MRI in cancer diagnosis
- Protein Degradation and Inhibitors
- Cancer survivorship and care
- CNS Lymphoma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Health and Wellbeing Research
Hospital Universitario 12 De Octubre
2020-2025
Centro de Investigación Biomédica en Red de Cáncer
2020-2025
Research Institute Hospital 12 de Octubre
2020-2023
Universidad Complutense de Madrid
2020
Background The impact of coronavirus disease 2019 (COVID-19) in haematological patients (HP) has not been comprehensively reported. Methods We analysed 39 with SARS-CoV-2 infection and malignancies. Clinical characteristics outcomes were compared to a matched control group 53 non-cancer COVID-19. Univariate multivariate analyses carried out assess the risk factors associated poor outcome. Results most frequent diseases lymphoma (30%) multiple myeloma (30%). Eighty-seven % HP developed...
Background/Objectives: This study aimed to determine whether interim PET/CT (iPET) scans could identify follicular lymphoma (FL) patients at high risk of relapse following first-line therapy. Methods: A total 117 FL who underwent iPET were included, with responses interpreted using the Deauville score (DS). Progression-free survival (PFS) was evaluated over a median follow-up 34 months. Results: Overall, 34% classified as (+), significantly worse estimated 5-year PFS compared (-) (34% vs....
Background/Objectives: This study aimed to determine whether interim PET/CT (iP-ET) scans could identify follicular lymphoma (FL) patients at high risk of relapse fol-lowing first-line therapy. Additionally, the potential cell-free DNA (cfDNA) analysis complement iPET in predicting outcomes was explored. Methods: A total 121 FL who underwent were included, with responses interpreted using Deauville score (DS). Progression-free survival (PFS) evaluated over a median follow-up 34 months....
The IPSS-M is a recently published score for risk stratification in myelodysplastic syndromes (MDS), based on clinical and molecular data. We aimed to evaluate its relevance treatment choice real-life setting.
Background CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores potential value ctDNA monitoring with an innovative signature personalized trackable mutations. Method Eleven patients treated anti-CD19 CAR T-cell were included. One did not respond and was excluded. Genomic profiling performed before starting lymphodepleting chemotherapy identify...
Non-Hodgkin lymphoma is a heterogeneous group of cancers that triggers bone marrow infiltration in 20–40% cases. Bone biopsy combination with visual assessment [18F]FDG PET/CT images used to assess the status. Despite potential both techniques, they still have limitations due subjectivity assessment. The present study aims develop models based on uptake at time diagnosis differentiate For this purpose, model trained for skeleton segmentation and U-Net architecture retrained from CT images....
Aggressive B-cell lymphomas (ABCL) represent a heterogeneous group of biologically different diseases with variable clinical outcomes.1, 2 Around one-third patients are not cured frontline treatment, and outcomes for this relapse/refractory (R/R) extremely poor conventional treatments.3-5 However, during the last years, several promising new therapies (NTs) have been progressively incorporated into treatment arsenal, such as monoclonal antibodies (MAs), cellular therapy T cells chimeric...
To assess the potential value of LiqBio as a complementary tool for diagnosis and surveillance BCL.This prospective multi-center study included 78 patients (25 follicular lymphomas (FL) 53 large B-cell (LBCL)). We performed next-generation sequencing (NGS) cfDNA paired gDNA tissue biopsies at compared mutational statuses. Also, through NGS LiqBio, we identified MRD biomarkers this novel LiqBio-MRD method with PET/CT in detecting follow-up.We mutations 71% 95% biopsies, found correlation...
The pathological increase of clonal IgM in Waldenström macroglobulinemia can be associated with acquired von Willebrand syndrome and a major risk bleeding symptoms this subgroup patients macroglobulinemia. Bruton tyrosine kinase inhibitor ibrutinib is one the approved treatments for symptomatic However, some controversy exists regarding use these high because its antiaggregant effect that could bleeding. Here, we present case patient progressively significant symptoms, who experienced rapid...
Background: Graft failure is an unusual complication of autologous stem cell transplantation (ASCT). It a life threatening where most patients (pts) die because infections or bleeding. defined by absence neutrophil recovery (>500 ANC) on day +28. can be primary (there wasn´t previous recovery) secondary (if there was). Ruling out infections, toxicity conditioning poor quality cells infused, the main cause still unknown. There no much literature about GF in ASCT. Treatments proposed are...
Abstract In the present study, we screened 84 Follicular Lymphoma patients for somatic mutations suitable as liquid biopsy MRD biomarkers using a targeted next-generation sequencing (NGS) panel. We found trackable in 95% of lymph node samples and 80% baseline samples. Then, use an ultra-deep approach with 2 · 10 − 4 sensitivity (LiqBio-MRD) to track those on 156 follow-up from 55 treated patients. Positive LiqBio-MRD correlated higher risk progression both at interim evaluation (HR 13.0, CI...
Background: The impact of coronavirus disease 2019 (COVID-19) on hematological patients has not been comprehensively reported to date. Methods: We analyzed 39 diagnosed with SARS-CoV-2 infection at our institution from March 7 April 7, 2020. Clinical characteristics and outcomes were compared a matched contemporary control group 53 non-cancer hospitalized center. Univariate multivariate analyses carried out assess the risk factors associated poor outcome. Results: Median patient age was 64.7...
Background: Follicular Lymphoma (FL) patients frequently achieve long remissions with frontline chemoimmunotherapy (CIT); nevertheless, a subset of will experience early progression and poor outcome. Fluoro-[18F]-deoxy-2-D-glucose positron emission tomography (PET/CT) liqBio-MRD performed at the end CIT induction can identify significantly higher risk relapse. The aim this study is to analyze if an interim PET/TC scan could earlier high-risk FL. Methods: We retrospectively identified 121...
Introduction: CAR-T therapy has produced a paradigm shift for the treatment of non-Hodgkin B-cell lymphomas (NHBcL). Strategies to optimize disease surveillance after this are increasingly necessary. This study aims explore potential value circulating tumor DNA (ctDNA) monitoring with an innovative signature personalized trackable mutations. Methods: Twenty-five NHBcL treated CD19 cell were included in 2 academic hospitals (10 follicular lymphoma-FL and 15 large B-cell-LBCL). Clinical...